VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Dicker on the Impact of Genetic Testing for Prostate Cancer

Adam P. Dicker, MD, PhD
Published: Tuesday, Apr 04, 2017



Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the impact of genetic testing for patients with prostate cancer.

Genetic testing has already effected how patients with metastatic prostate cancer are treated, Dicker states.

The standard of care at Thomas Jefferson University, is to do a biopsy of the metastatic site. Then, next-generation sequencing is used and if results determine an alteration in a DNA damaged pathway, the patient may receive a PARP inhibitor or platinum-based therapy, explains Dicker.
 


Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the impact of genetic testing for patients with prostate cancer.

Genetic testing has already effected how patients with metastatic prostate cancer are treated, Dicker states.

The standard of care at Thomas Jefferson University, is to do a biopsy of the metastatic site. Then, next-generation sequencing is used and if results determine an alteration in a DNA damaged pathway, the patient may receive a PARP inhibitor or platinum-based therapy, explains Dicker.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x